The 36th ISGE concluded successfully: Juhe Biotech's research results on endometrial cancer methylation attracted widespread attention

On May 26, 2024, the three-day 36th ISGE Academic Conference and Peking University Gynecologic Oncology Academic Conference was successfully concluded at the Beijing International Convention Center. ISGE has landed in China for the first time in more than 30 years since its establishment in Europe. This conference set up 1 main venue, 6 workshops, and 17 sub-forums. More than 50 internationally renowned and nearly 100 domestic gynecology experts were invited to give wonderful reports and show high-level standardized operation demonstrations. The content was rich and exciting.

On May 26, a special academic meeting entitled "The application value of CDO1 and CELF4 methylation detection in cervical exfoliated cells in endometrial cancer screening" hosted by Professor Xue Fengxia of Tianjin Medical University General Hospital and presented by Professor Li Lei of Peking Union Medical College Hospital attracted great attention from the participating teachers.

Starting from the current challenges and innovative technologies in the diagnosis and treatment of endometrial cancer, Professor Li Lei shared in detail the research progress and data results of CDO1/CELF4 dual gene methylation applied to endometrial cancer.

In recent years, the incidence of endometrial cancer has been on the rise and younger. According to the 2020 Global Cancer Data, the number of new cases of endometrial cancer in China exceeds 80,000 per year, with an incidence rate of 63.4/100,000 and a mortality rate of 21.8/100,000. It has become one of the most common and most malignant gynecological tumors in Chinese women. Early diagnosis and early treatment are necessary means to prevent endometrial cancer. The 5-year survival rate of stage I is greater than 90%, and that of stage IV is less than 20%.

Conventional vaginal ultrasound, hysteroscopic biopsy/curettage, cytology and other methods have slowed down the development of endometrial cancer screening and diagnosis methods due to technical and clinical diagnosis limitations. The National "14th Five-Year Plan" National Key R&D Plan "Reproductive Health and Women and Children's Health Protection" has identified early screening of endometrial cancer, the establishment of a precise diagnosis and treatment system, and the development of key technologies as key projects in 2022. Endometrial cancer screening is imminent.

Hypermethylation is a hallmark event in the development of cancer and has become a hot topic in cancer diagnosis and treatment research. High DNA methylation is an early event in the process of high-grade CIN lesions developing into invasive cancer and is crucial for the accurate identification of CIN2+ lesions. This provides an opportunity for the application of methylation. In recent years, the study of CDO1/CELF4 dual gene methylation in endometrial cancer has received increasing attention, and many data results have been published.

A clinical trial led by Peking Union Medical College Hospital showed that CDO1/CELF4 double gene methylation has good detection sensitivity and specificity in endometrial cancer screening. In addition, Peking Union Medical College Hospital has teamed up with 14 other research units across the country to launch the world's first large-scale endometrial cancer screening multi-center clinical research plan (EndoMethy), and conducted complete Phase I, II, and III clinical trials. . Data show that the sensitivity and specificity of CDO1/CELF4 dual-target methylation detection of endometrial cancer through cervical exfoliated cells are significantly better than the judgment effect based on symptoms and imaging, suggesting that methylation technology has the potential for non-invasive early screening. feasibility of diagnostic applications.

Professor Li Lei shared the latest multi-faceted clinical applications of CDO1/CELF4 double gene methylation in the diagnosis of endometrial cancer.

01

A study published in the Chinese Medical Journal showed that the sensitivity and specificity of CDO1/CELF4 dual gene methylation in postmenopausal women were 87.5% and 90.8%, respectively. Transvaginal ultrasound (TUV) combined with DNA methylation detection can further increase the sensitivity to 100.0%, which is better than other non-invasive clinical solutions.

02

The Third Xiangya Hospital of Central South University and Juhe Biotechnology jointly conducted a study - using the area under the receiver operating characteristic curve (AUC) to analyze the detection efficiency of DNA methylation detection for endometrial cancer in women of childbearing age. The results showed that the AUC of CDO1/CELF4 methylation for diagnosing endometrial cancer was as high as 0.90, and the accuracy of methylation detection was better than other non-invasive clinical solutions. The results have been published in the Chinese Journal of Laboratory Medicine.

03

A study jointly published by Gansu Provincial Maternal and Child Health Hospital and Juhe Bio in the journal "Cytojournal" showed that in women with postmenopausal bleeding, the sensitivity of CDO1/CELF4 methylation detection was 87.5%, the specificity was 95.9%, and the detection rate of type II EC could reach 100%, which is an effective diversion strategy for endometrial cancer.

04

Cangzhou Central Hospital published in the journal "Frontiers in oncology" that tested CDO1/CELF4 methylation in 607 women with indications for endometrial biopsy. The results suggest that CDO1/CELF4 hypermethylation can be used as a triage biomarker for malignant lesions of endometrial cancer (AH/EC).

In the future, CDO1/CELF4 dual gene methylation will be further explored in the screening of high-risk populations for endometrial cancer, stratified management of populations with genital tract bleeding, monitoring and follow-up, etc., in order to obtain high-quality clinical multi-center big data, formulate clinical expert application consensus, and establish Chinese-style diagnosis and treatment guidelines.

Finally, Professor Xue highly praised Professor Li Lei's research results and report content. At the same time, combined with the experience of participating in the "Application Research of Methylation in Gynecological Tumors" project just launched on May 11, he affirmed the potential and value of CDO1/CELF4 dual gene methylation in endometrial cancer screening, which is a new technology worthy of clinical attention and application. He hopes that the product will obtain the certificate as soon as possible and contribute to women's health.

About CISPOLY

Beijing Qrigin-Poly Bio-tec Co., Ltd. is a technology company driven by innovative technology and focusing on health. CISPOLY is a pioneer in the field of early diagnosis of gynecological tumors. With exclusive technology and patented markers as the core, it has developed early diagnosis products for gynecological tumors such as cervical cancer, endometrial cancer, and ovarian cancer, filling the gap in this field.

As women pay more and more attention to their own health, the women's health market will have great potential. In addition to the gynecological tumor early screening and early diagnosis product line, CISPOLY will also establish more women's health-related product pipelines in the future to create a leading technology innovation company in the women's health market.